Free Daily Podcast Summary
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes: Daily Summaries Delivered
by BZ Group
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Host voices are AI-created.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Today17 min
EASD 2026 Debrief: Type 2 Diabetes Care Moves Earlier & Foundayo Meets a Heart-Safety Bar
The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus reportmoves GLP-1 and SGLT2 drugs earlier in type 2 diabetes care, potentially from diagnosis, and prefers weight-lowering drugs for people with overweight orobesity. Lilly's ACHIEVE-4 put its oral GLP-1 pill Foundayo against insulin and met a heart-safety bar. Real-world data arrived from Novo on stepping up semaglutide versus switching, from Abbott on continuous glucose monitors, and from a Nordic study on semaglutide and pancreatic cancer. Plus the journal papers on retatrutide, survodutide and petrelintide, type 1 diabetes screening in children across Europe, and what to watch: Lilly and Novo results and ObesityWeek.0:00 Cold open and introduction1:12 Story of the Congress: type 2 diabetes care moves earlier2:54 Lilly's Foundayo vs insulin: ACHIEVE-4 heart safety4:57 Real-world evidence: Novo's switch data, Abbott's glucose monitors, semaglutide and pancreatic cancer9:20 Obesity: the retatrutide, survodutide and petrelintide papers13:59 Type 1 diabetes: screening children across Europe15:51 What to watch: Lilly and Novo results, ObesityWeekAlex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com.
- Today8 min
Genmab's Epkinly Wins Frontline Trial & Vaxcyte's Vaccine Passes With Caveats
Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met its pivotal immune-response framework, with two serotypes clearing only a looser threshold against Merck's CAPVAXIVE—not proof of disease prevention. Deals span GE HealthCare–SOFIE and PET tracer FAPI-74, Shionogi–IntraBio and AQNEURSA in rare neurology, and CSL–Alentis for kidney-disease antibody lixudebart. CMS finalized rules for future prescription-drug files that could improve market-access pricing visibility if the schedule holds.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
- Yesterday46 min
Week in Review | Lilly's Retatrutide Dose Data, Novartis' RNA Deal & Jaypirca's Approval
Lilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without a known 17p deletion. Novartis agrees to $575 million upfront for Abogen's autoimmune RNA program, and Sanofi-Regeneron expands its long-acting antibody partnership. Ovarian-cancer datasets, Mirum's hepatitis D results and uniQure's Huntington's filing show why patient populations and control groups matter. CMS rebates and medicine tariffs reach manufacturer economics, alongside retina, respiratory and rare-disease updates.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
- Yesterday25 min
ASTRO 2026 Debrief: Who Still Needs Hormone Therapy & Protons vs Photons in Liver Cancer
The Pharma Closeout's ASTRO 2026 Debrief covers the readouts from the American Society for Radiation Oncology meeting that matter for drug,diagnostic and payer strategy. Fourteen-year RTOG 0815 data re-open how much hormone therapy men need with prostate radiation, as Veracyte's Decipher andArtera compete to decide who can skip it. The NRG-GI003 plenary showed no survival improvement for protons over photons in liver cancer, Novocure's TRIDENT timing trial missed, and new data arrived on PSMA imaging, radioligands, SBRT versus surgery and lung immunotherapy after SABR. Plus what to watch: theLantheus shareholder vote on the Curium takeover.0:00 Introduction1:17 Story of the Congress: who still needs hormone therapy with radiation9:29 Prostate: PSMA imaging, PSMA-guided radiation and SBRT vs surgery13:20 Radioligand therapy at a radiation meeting17:08 Glioblastoma: TRIDENT and Tumor Treating Fields timing18:51 Lung: immunotherapy after SABR20:46 Liver and rectal: protons vs photons, and PD-1 in rectal cancer23:45 Breast: endocrine adherence and skipping radiation24:51 What to watch: the Lantheus voteAlex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at thepharmacloseout.com.
- 3 days ago8 min
Daily Roundup | Jaypirca Adds a First-Line CLL Choice & Novartis Signs $575M Abogen License
Delayed Friday edition, recorded October 2. Lilly's Jaypirca (pirtobrutinib) gains first-line approval for adults with CLL/SLL without a known 17p deletion—but how does a trial against older chemotherapy guide today's treatment choice? Novartis agrees to $575 million upfront for Abogen's early-stage RNA medicine ABO2203, with closing still pending and autoimmune benefit unproven. Also: Pfizer's Litfulo (ritlecitinib) advances toward vitiligo filings; Biogen reports longer-term litifilimab results in cutaneous lupus without a continuing placebo comparison; and Bayer plans a $2.2 billion Ohio manufacturing site.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
- 4 days ago8 min
Survodutide Phase 3 Comes With GI Tolerability Cost & Trevogrumab Trims Lean-Tissue Loss on Scans
Boehringer's survodutide reached up to 13.1% weight loss in Phase 3 assuming patients stayed on treatment, but GI-related dropouts complicate its place in obesity and Type 2 diabetes. CMS's final GLOBE rule tests international prices in Medicare Part B rebates: what changes for patients and doctors? Regeneron's trevogrumab reduced lean-mass loss on scans with semaglutide, without proving greater strength. Also: Sanofi and Regeneron expand their Dupixent alliance with four long-acting antibodies; Foghorn and Lilly stop FHD-909 expansion after insufficient efficacy; and Wave's WVE-006 gets a potential registration path in alpha-1 antitrypsin deficiency.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
- 5 days ago11 min
Daily Roundup | Lilly's amylin add-on brings more weight loss and more dropouts & Rafael plans NDA after NPC miss
September 30 edition, released October 1. Date references in the audio are anchored to September 30.Lilly's EloraTZP (eloralintide plus tirzepatide) reached 23.3% weight loss vs 14.8% for tirzepatide in a secondary Phase 2b comparison, while more patients stopped over adverse events. Rafael Holdings' Trappsol Cyclo missed its Phase 3 TRANSPORT-NPC goal in Niemann-Pick disease type C, yet a fourth-quarter filing is still planned. The daily roundup covers Roche's fenebrutinib Priority Review in MS, Merck's tulisokibart in hidradenitis suppurativa, Pierre Fabre's Ebvallo (tabelecleucel) resubmission and NorthStar's actinium-225 financing. Plus Connect Biopharma's rademikibart in COPD flares, with its safety caveats.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
- 6 days ago14 min
Daily Roundup | uniQure's Mixed Huntington's Readout & AstraZeneca's $2B Summit Deal
September 29 edition: uniQure's four-year Huntington's readout is mixed, while its filing rests on earlier data. AstraZeneca agrees to invest $2 billion in Summit alongside a cancer-combination program, without acquiring Summit's drug rights. In the roundup: Veracyte's retrospective Decipher analysis in prostate cancer; FDA approval of Teva's Xgeva biosimilar; and Novo's license to Hengrui's early oral GLP-1/GIP program. Invivyd reports tolerability, not protection, results for VYD2311, and we examine the September 29 implementation of Section 232 drug tariffs.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Get The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Tech News Daily
Daily summaries of the latest developments in artificial intelligence, robotics, cybersecurity, gadgets, and apps.
Pharmacy Podcast Network
A podcast network featuring dozens of shows on pharmacy practice, policy, and innovation, with interviews across clinical and industry specialties.
In the Interim...
Explores Bayesian statistics and adaptive clinical trial designs in medical research with insights from industry experts.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
AI News Daily
A daily summary of the latest developments in artificial intelligence, covering machine learning, robotics, automation, and AI ethics.
Stock Movers
Short conversations analyzing today's biggest gainers and losers in global stock markets across major sectors.
Becker’s Healthcare Podcast
Daily 15-minute episodes covering U.S. healthcare news, analysis, and insights from industry leaders.
🎙️ Science News Daily | Peer Review'd
Daily science news covering space, biology, physics, and technology breakthroughs.
GSD Mode Podcast
Real estate professionals and entrepreneurs learn actionable strategies to grow their businesses through interviews and expert advice.
The Best One Yet
A daily 20-minute podcast breaking down the three key business stories with sharp, accessible takes.
Health vs Hype with the American Medical Association
A medical expert debunks viral health trends and misinformation with science-backed insights from physicians.
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
About The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Host voices are AI-created.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes daily summary?
It's a free AI-powered email that summarizes new episodes of The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BZ Group.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes release new episodes?
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes publishes daily. Our AI generates a summary within hours of each new episode.
What topics does The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes cover?
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.